Abstracts tagged "methotrexate (MTX)"

Abstract Number: 2369 • 2013 ACR/ARHP Annual Meeting
Long-Term Outcome Of Infliximab Therapy In Rheumatoid Arthritis Patients: Results From Japanese Multicenter Registry System
Nobunori Takahashi¹, Toshihisa Kojima², Atsushi Kaneko³, Yuji Hirano⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ³Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan
Background/Purpose: After demonstration of effectiveness of anti-tumor necrosis factor (TNF) agents in patients with rheumatoid arthritis (RA), their use has become common practice in treating…
Abstract Number: 1355 • 2013 ACR/ARHP Annual Meeting
Subcutaneous Administration Of Methotrexate With a Prefilled Autoinjector Pen Results In a Higher Relative Bioavailability Compared To Oral Administration Of Methotrexate
Uwe Pichlmeier and Kay-Uwe Heuer, medac GmbH, Wedel, Germany
Background/Purpose: Methotrexate (MTX) is commonly used in the treatment of RA, psoriasis, and psoriatic arthritis. Subcutaneously administered MTX is well absorbed and appears to overcome…
Abstract Number: 2341 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Adalimumab Plus Methotrexate Therapy In Rheumatoid Arthritis Non-Responders Receiving Methotrexate Monotherapy Or Adalimumab Combination Therapy: Results From The Optima Trial
Josef S. Smolen¹, Ronald F. van Vollenhoven², Roy Fleischmann³, Paul Emery⁴, Stefan Florentinus⁵, Suchitrita S. Rathmann⁶, Anabela Cardoso⁷, Hartmut Kupper⁸ and Arthur Kavanaugh⁹, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²The Karolinska Institute, Stockholm, Sweden, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Leeds Teaching Hospital, Leeds, United Kingdom, ⁵AbbVie, Rungis, France, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie, Amadora, Portugal, ⁸AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁹University of California, San Diego, La Jolla, CA
Background/Purpose: EULAR recommendations advocate Methotrexate (MTX) as first line therapy. For patients (pts) who fail to attain remission or low disease activity (LDA) after 6…
Abstract Number: 1354 • 2013 ACR/ARHP Annual Meeting
Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen
Jaime Pachon¹, Alan Kivitz², Kay-Uwe Heuer³ and Uwe Pichlmeier³, ¹Arthritis and Rheumatic Care Center, Miami Research Associates, South Miami, FL, ²Altoona Center for Clinical Research, Duncansville, PA, ³medac GmbH, Wedel, Germany
Background/Purpose: Methotrexate (MTX) is the most commonly used and recommended DMARD for the treatment of RA. SC administered MTX is well absorbed and appears to…
Abstract Number: 2321 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 24-Week Randomized Controlled Trial and Open-Label Extension Study
Josef S. Smolen¹, Ronald van Vollenhoven², Arthur Kavanaugh³, Vibeke Strand⁴, Jiri Vencovsky⁵, Michael H. Schiff⁶, Robert Landewé⁷, Boulos Haraoui⁸, Susan Walker⁹ and Désirée van der Heijde¹⁰, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA, ⁴Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁵Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Rheumatology Division, University of Colorado, Denver, CO, ⁷Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, ⁸Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁹UCB Pharma, Raleigh, NC, ¹⁰Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the RAPID2 randomized controlled trial (RCT; NCT00160602), certolizumab pegol (CZP) +MTX every 2 weeks (Q2W) improved signs and symptoms of rheumatoid arthritis (RA)…
Abstract Number: 1056 • 2013 ACR/ARHP Annual Meeting
Adherence To Methotrexate Therapy Among Patients With Rheumatoid Arthritis In Denmark: A Registry Based Cohort Study
Henning Bliddal¹, Robin Christensen², Mikkel Østergaard³, Tove Lorenzen⁴, Michael Sejer Hansen⁵, Peter Vestergaard⁶ and Stine A Eriksen⁶, ¹The Parker Institute, Copenhagen, Denmark, ²Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, ³Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁴Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁵Gildhøj Privathospital, Copenhagen, Denmark, ⁶Medicine, Aalborg University, Aalborg, Denmark
Background/Purpose: Conflicting data have been presented on patient compliance with methotrexate (MTX) prescription. A Danish study found a mean period of 12.3% of the prescribed…
Abstract Number: 2229 • 2013 ACR/ARHP Annual Meeting
Alleviation Of Collagen-Induced Arthritis By Multifunctional Nanoparticle Containing Methotrexate
You-Jung Ha¹, Sun-Mi Lee², Ji-Hee Lim¹, Hyung-Joon Kim², Sang-Won Lee³, Soo Kon Lee⁴, Kyung-Hwa Yoo² and Yong-Beom Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ²Nanomedical Graduate Program, Department of Physics, Yonsei University, Seoul, South Korea, ³Department of Internal Medicine, Yonsei University College of Medicine, Seoul, NV, South Korea, ⁴Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ⁵Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Methotrexate (MTX) is the most widely used disease-modifying anti-rheumatic drugs for the treatment of rheumatoid arthritis (RA). Despite of its efficacy, the continuous use…
Abstract Number: 748 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Methotrexate For Remission Induction and Maintenance In Granulomatosis With Polyangiitis In Routine Clinical Practice
Megan L. Krause¹, Misbah Baqir², Rodrigo Cartin-Ceba³, Tobias Peikert⁴, Karina Keogh⁴ and Ulrich Specks⁴, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Pulmonary/Critical Care, Mayo Clinic, Rochester, MN, ³Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Methotrexate has been shown to be effective for both induction (non-severe disease) and maintenance of remission in patients with Granulomatosis with Polyangiitis (GPA) in…
Abstract Number: 1977 • 2013 ACR/ARHP Annual Meeting
Remission At 3 Or 6 Months and Radiographic Non-Progression At 12 Months In Methotrexate-Naïve Rheumatoid Arthritis Patients Treated With Tofacitinib Or Methotrexate: A Post-Hoc Analysis Of The ORAL Start Trial
V. Strand¹, D. van der Heijde², R. Landewe³, E. B. Lee⁴, B. Wilkinson⁵, S. H. Zwillich⁵, J. Bradley⁵, C. Mebus⁵, B. Benda⁶ and D. Gruben⁵, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Seoul National University, Seoul, South Korea, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of RA. The importance of “treat to target” in RA to attain…
Abstract Number: 482 • 2013 ACR/ARHP Annual Meeting
Methotrexate Use At Infliximab Initiation and Impact On Treatment Outcomes: An Analysis From A Canadian Registry
Denis Choquette¹, J. Carter Thorne², John T. Kelsall³, Michel Zummer⁴, Michael Starr⁵, Maqbool K. Sheriff⁶, William G. Bensen⁷, Andrew Chow⁸, Philip Baer⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Allen J. Lehman¹², Susan M. Otawa¹² and May Shawi¹³, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁴Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁵Montreal General Hospital, Montreal, QC, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁸University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁹Private Practice, Scarborough, ON, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of infliximab (IFX)1. Data on the benefits of combination…
Abstract Number: 1711 • 2013 ACR/ARHP Annual Meeting
Folic Acid Prescription Among Older Adult Methotrexate Initiators Is Poor
Gabriela Schmajuk¹, Jinoos Yazdany², Yinghui Miao³, David I. Daikh⁴ and Michael Steinman³, ¹Rheumatology, UCSF / San Francisco VA Medical Center, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Division of Geriatrics, UCSF, San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Methotrexate (MTX) is the most commonly used disease modifying agent for rheumatoid arthritis (RA), although liver enzyme (LFT) elevations limit its use in some…
Abstract Number: 460 • 2013 ACR/ARHP Annual Meeting
Comparative Efficacy Of Novel Disease-Modifying Antirheumatic Drugs As Monotherapy and In Combination With Methotrexate In Rheumatoid Arthritis Patients With An Inadequate Response To Traditional Disease-Modifying Antirheumatic Drugs: A Network Meta-Analysis
Felicity Buckley¹, Axel Finckh², Thomas W.J. Huizinga³, Fred Dejonckheere⁴ and Jeroen P. Jansen¹, ¹MAPI Consultancy, Boston, MA, ²Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: To compare ACR responses of novel DMARDs as monotherapy or in combination with methotrexate (MTX), including subcutaneous (SC) abatacept and SC tocilizumab (TCZ), in…
Abstract Number: 1822 • 2012 ACR/ARHP Annual Meeting
Liver Toxicity Monitoring and Its Impact On Methotrexate Discontinuation in a National Cohort of Veterans
Gabriela Schmajuk¹, Yinghui Miao², Jinoos Yazdany³, Mary Margaretten⁴ and Michael Steinman², ¹Rheumatology, UCSF / San Francisco VA Medical Center, San Francisco, CA, ²Division of Geriatrics, UCSF, San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: The National Quality Forum recently endorsed a controversial quality measure that assesses liver toxicity monitoring for patients receiving oral methotrexate (MTX). Using national data…
Abstract Number: 352 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis: Influence of Methotrexate, Anti-TNF and Rituximab On the Immune Response to Influenza and Pneumococcal Vaccines in Patients with Rheumatoïd Arthritis
Charlotte Hua¹, Thomas Barnetche², Bernard Combe³ and Jacques Morel⁴, ¹Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Vaccines against influenza and streptococcus pneumonia are currently recommended for patients with rheumatoid arthritis (RA). This meta-analysis assesses current literature data on the impact…
Abstract Number: 1827 • 2012 ACR/ARHP Annual Meeting
Factors That Impact Work Productivity in the Preserve Trial: A Randomized Controlled Trial of Combination Etanercept-Methotrexate Therapy in Patients with Moderately Active Rheumatoid Arthritis
Vibeke Strand¹, Thomas V. Jones², Wenzhi Li³, Andrew S. Koenig⁴ and Sameer Kotak⁵, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ²Inflammation Specialty Care, Pfizer, Inc, Collegeville, PA, ³Pfizer Inc., Collegeville, PA, ⁴Specialty Care Business Unit, Pfizer Inc., Collegeville, PA, ⁵Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Active joint inflammation and structural damage in patients with rheumatoid arthritis (RA) often result in impaired physical function and ultimately work disability.1,2 Lost productivity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].